产品
编 号：F190844
分子式：C34H32ClFeN4O4
分子量：651.94
分子式：C34H32ClFeN4O4
分子量：651.94
产品类型
规格
价格
是否有货
500mg
320
In-stock
1g
400
In-stock
5g
1440
In-stock
结构图
CAS No: 16009-13-5
产品详情
生物活性：
Hemin is an iron-containing porphyrin. Hemin is an Heme oxygenase (HO)-1 inducer.
体内研究：
Following the i.p. administration of Hemin (100 μmol/kg), the HO-1 level in the renal cortex begins to increase gradually. The HO-1 level reaches its peak 24 h after Hemin preconditioning. HO-1 is expressed mainly in the renal tubules. The HO-2 level in the kidney does not change following Hemin preconditioning.
体外研究：
Hemin and PGJ2, used as positive controls, strongly increase both expression and activity of HMOX after 4 and 12 h, respectively. Indeed, a significant effect is found of 30 μM Hemin on cell proliferation in all used cell lines after 48 h, which is dose-dependent. Hemin treatment decreases cell proliferation to 62±5 %, 51±3 %, and 38±8 % in PA-TU-8902, BxPC-3 and MiaPaCa-2 cancer cells, respectively, with pHemin 相关抗体:
Hemin is an iron-containing porphyrin. Hemin is an Heme oxygenase (HO)-1 inducer.
体内研究：
Following the i.p. administration of Hemin (100 μmol/kg), the HO-1 level in the renal cortex begins to increase gradually. The HO-1 level reaches its peak 24 h after Hemin preconditioning. HO-1 is expressed mainly in the renal tubules. The HO-2 level in the kidney does not change following Hemin preconditioning.
体外研究：
Hemin and PGJ2, used as positive controls, strongly increase both expression and activity of HMOX after 4 and 12 h, respectively. Indeed, a significant effect is found of 30 μM Hemin on cell proliferation in all used cell lines after 48 h, which is dose-dependent. Hemin treatment decreases cell proliferation to 62±5 %, 51±3 %, and 38±8 % in PA-TU-8902, BxPC-3 and MiaPaCa-2 cancer cells, respectively, with pHemin 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备